Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 4

1(20.0%)

5Total

N/A(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06266351Completed

EVALUATION of CATS TONOMETER PRISM in LASIK SUBJECTS

Role: lead

NCT04180111Unknown

Cross Linking Corneal Biomechanical Evaluation of CATS Tonometer Prism

Role: lead

NCT04178863Phase 4Unknown

CATS Tonometer IOP Reduction Latanoprost Verses Timolol

Role: lead

NCT03025945Not ApplicableCompleted

Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo

Role: lead

NCT02990169Not ApplicableCompleted

Clinical Evaluation of CATS Tonometer Prism

Role: lead

NCT02910362Not ApplicableCompleted

Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines

Role: lead

NCT02989909Not ApplicableCompleted

Clinical Evaluation of CATS Tonometer Prism

Role: lead

All 7 trials loaded